Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 5, 2025Frontiers in ImmunologyOpen Access

Durable response of primary cardiac lymphoma after autologous stem cell transplantation and sequential CAR-T therapy: a case report and literature review

View Full Paper
Ask AI
Bookmark
Share

Authors

GWGe WangXZXiaoxi ZhouPWPengcheng Wang

Discussion

Loading...

Member takes

Overview

Case report reveals sustained complete response in primary cardiac lymphoma following ASCT and CAR-T therapy, highlighting treatment potential.

Key Points

  • The patient achieved sustained complete response after a combination of ASCT and sequential CAR-T therapy, demonstrating effectiveness.
  • Complete response was attained by month 3 and maintained for one year, highlighting the potential of novel therapies in rare lymphoma cases.
  • Management of immune effector cell-associated toxicity involved granulocyte colony-stimulating factor, showing feasibility in treatment.
  • This case underscores the diagnostic and therapeutic challenges in primary cardiac lymphoma, warranting further investigation.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68c23922b210217d6477a44chttps://doi.org/10.3389/fimmu.2025.1581654
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CART–ASCT–CART2 sandwich regimen as frontline therapy: A phase II trial in patients with primary plasma cell leukemia2025 · 2 citations
  2. 2CAR T-cell therapy for refractory/relapsed primary breast lymphoma: A retrospective cohort study2025
  3. 3Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma2025
  4. 4Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report2025
  5. 5A real-world analysis of primary mediastinal large B-cell lymphoma: A single center study in China2025